Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue
Total revenue	$ 736,137	$ 967,205	$ 1,649,581	$ 1,436,950
Operating expenses
Cost of products sold	714,392	646,389	1,306,770	938,386
Cost of services	204,102	15,650	332,408	46,212
Research and development	1,388,792	2,273,756	3,201,624	4,590,197
General and administrative	2,425,007	2,134,266	4,848,960	4,759,319
Sales and marketing	1,160,200	1,169,349	2,186,287	2,220,781
Total operating expenses	5,892,493	6,239,410	11,876,049	12,554,895
Operating loss	(5,156,356)	(5,272,205)	(10,226,468)	(11,117,945)
Other (expense) income
Interest and other income	31,215	13,851	61,323	16,972
Interest expense	(684,498)	(779,912)	(1,301,796)	(2,049,493)
Foreign currency transaction (losses) gains	(60,401)	271,967	(152,396)	470,707
Change in fair value of derivative financial instruments	42,717	(74,116)	55,411	35,628
Total other expense	(670,967)	(568,210)	(1,337,458)	(1,526,186)
Loss before income taxes	(5,827,323)	(5,840,415)	(11,563,926)	(12,644,131)
Provision for income taxes
Net loss	(5,827,323)	(5,840,415)	(11,563,926)	(12,644,131)
Net loss available to common stockholders	$ (5,827,323)	$ (5,840,415)	$ (11,563,926)	$ (12,644,131)
Net loss per common share – basic (in Dollars per share)	$ (0.93)	$ (2.51)	$ (2.13)	$ (5.43)
Weighted average shares outstanding – basic (in Shares)	6,246,326	2,328,725	5,424,542	2,326,485
Net loss	$ (5,827,323)	$ (5,840,415)	$ (11,563,926)	$ (12,644,131)
Other comprehensive (loss) income – foreign currency translation	(113,704)	(1,227,142)	39,363	(1,710,991)
Comprehensive loss	(5,941,027)	(7,067,557)	(11,524,563)	(14,355,122)
Product sales
Revenue
Total revenue	439,672	889,271	850,569	1,255,323
Laboratory services
Revenue
Total revenue	44,003	20,570	65,676	63,499
Collaboration revenue
Revenue
Total revenue	$ 252,462	$ 57,364	$ 733,336	$ 118,128